Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era

The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamdy, Sherif M, Abdel-Naseer, Maged, Shehata, Hatem S, Shalaby, Nevin M, Hassan, Amr, Elmazny, Alaa, Shaker, Ehab, Nada, Mona A F, Ahmed, Sandra M, Hegazy, Mohamed I, Mourad, Husam S, Abdelalim, Ahmed, Magdy, Rehab, Othman, Alshimaa S, Mekkawy, Doaa A, Kishk, Nirmeen A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443007/
https://www.ncbi.nlm.nih.gov/pubmed/32884277
http://dx.doi.org/10.2147/TCRM.S261753
Descripción
Sumario:The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.

Ejemplares similares